Immunomodulation via inhibition of T lymphocyte proliferation

Immunomodulation via inhibition of T lymphocyte proliferation is a therapeutic strategy rather than a single molecular target. It describes the process of suppressing the clonal expansion of T cells, which is a central event in the adaptive immune response (Nature Reviews Immunology: T cell activation, 2020). This effect is typically achieved by targeting specific intracellular signaling pathways or metabolic enzymes essential for T-cell activation and division (StatPearls: Immunosuppressants, 2023). Key molecular targets that mediate this effect include calcineurin, which is required for IL-2 transcription, and the mammalian target of rapamycin (mTOR), which regulates cell cycle progression (Journal of Clinical Investigation: mTOR and T cells, 2014). Additionally, the inhibition of de novo nucleotide synthesis through enzymes like IMPDH or DHODH can effectively halt T-cell proliferation (Frontiers in Immunology: Calcineurin Inhibitors, 2021). Clinically, this approach is fundamental in preventing organ transplant rejection and managing various autoimmune and inflammatory disorders. However, because it suppresses broad immune functions, it carries significant risks such as opportunistic infections and decreased immunosurveillance against tumors.

Other names

T-cell proliferation inhibitionT-lymphocyte suppressionImmunosuppression of T-cells

Inhibition of T lymphocyte proliferation is achieved through various molecular mechanisms, including the inhibition of calcineurin to prevent IL-2 transcription, the inhibition of mTOR to block cytokine-driven cell cycle progression, or the disruption of de novo purine/pyrimidine synthesis required for DNA replication (StatPearls: Immunosuppressants, 2023).